Incyte Corporation (LON:0J9P)

Market Cap	11.04B
Revenue (ttm)	3.39B
Net Income (ttm)	26.05M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	423.74
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,123
Average Volume	2,521
Open	72.02
Previous Close	70.83
Day's Range	71.53 - 72.53
52-Week Range	50.81 - 75.42
Beta	0.70
RSI	53.21
Earnings Date	Feb 4, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1991
• Employees: 2,617
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J9P

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD